Background: Helicobacter pylori eradication therapy was approved in Japan for the
lymphoma, and Helicobacter pylori eradication induces clinical and histological regression of the disease in the majority of cases, as first reported by Wotherspoon et al. 3 Approximately 60%-80% of H. pylori-positive gastric MALT lymphomas achieve complete histological response after H. pylori eradication. [3] [4] [5] H. pylori eradication therapy is currently recommended as the first-line treatment for all patients with gastric MALT lymphoma, as described in guidelines from the United States, Europe, and Japan. [6] [7] [8] [9] [10] [11] In Japan, H. pylori eradication therapy was approved for the treatment of H. pylori-positive gastric MALT lymphoma in 2010, based on single-center retrospective studies. 12, 13 To date, however, no well-controlled, prospective, multicenter studies have been reported from Japan. We therefore conducted a prospective, nationwide, multicenter study to confirm the efficacy and safety of this treatment in Japan.
| MATERIAL S AND ME THODS

| Subjects and study design
This prospective, multicenter trial (ClinicalTrials.gov, NCT01264822)
was conducted at 34 hospitals in Japan from December 2010 to H. pylori status was determined according to histology, culture, rapid urease test, 13 C urea breath test (UBT), H. pylori stool antigen test (HpSA), and/or serology. H. pylori infection was judged as positive if at least one of the tests yielded a positive result, and as negative when all tests were negative. The endoscopic type of MALT lymphoma was classified as superficial, ulcerative, elevated, or other. 15 Endoscopic ultrasound (EUS) was performed to evaluate the depth of tumor invasion and degree of perigastric lymphadenopathy. 15 The status of t(11;18)(q21;q21)/API2-MALT1 was investigated by reverse-transcription polymerase chain reaction and/or fluorescence in situ hybridization (FISH). twice a day for 7 days, as a regimen approved by the Japanese governmental healthcare system. Successful eradication was basically evaluated using the UBT or HpSA according to the Maastricht IV consensus. 10 After successful eradication, the follow-up observation was started from the first day of successful H. pylori eradication, and the related parameters including histopathology and transition to secondary treatment for MALT lymphoma were evaluated. The follow-up period after eradication therapy in each patient was basically set to ≥24 months. 
| Histological evaluation
| Secondary treatment for patients with treatment failure
When a lymphoma was judged by a physician as not responsive to eradication treatment, the patients underwent other oncological treatments (radiotherapy, chemotherapy, rituximab, or surgical resection). They were defined as in transition to secondary treatment.
The timing of transfer to secondary treatment was judged by the physician, because this trial was not an interventional study, but an observation study, as defined in the Japanese Ethical Rule for clinical observation studies. 
| Endpoints and statistical analysis
| RE SULTS
| Clinical features of patients
Among the 108 registered patients, one was excluded for a registration violation and 107 were included in the safety analysis set.
Among the 107 patients in the safety analysis set, 10 patients were excluded for either a lack of efficacy evaluation (n = 4), using a regimen unapproved in Japan (n = 4), or lacking confirmed histological evidence of MALT lymphoma (n = 2). The remaining 97 patients were included in the efficacy analysis set.
As shown in Table 1 
| Successful Helicobacter pylori eradication
Successful H. pylori eradication was achieved in 86 of 97 patients (88.7%). The eradication rate was 87.8% (79/90) with CAM-based therapy and 100.0% (7/7) with MNZ-based therapy. All patients with failure of CAM-based therapy were treated using MNZ-based therapy. UBT (n = 87), HpSA (n = 1), culture (n = 6), and histology (n = 3) were used to identify successful eradication. Median time to successful eradication after completion of eradication therapy was 6.9 weeks (range, 4.0-24.7 weeks).
| Response to Helicobacter pylori eradication therapy
Clinical course and outcomes in the efficacy analysis set of 97 patients are shown in Figure 1 . CR was achieved in 86.6% of patients (84/97) using H. pylori eradication treatment alone. The median interval to CR after the start of the successful eradication treatment was 5.3 months (range, 2.0-44.7 months), and 61.9% of CR patients (52/84) achieved CR within 6 months after starting successful eradication treatment.
The clinical characteristics and CR rates in the 97 patients are shown in Table 1 . Cases with superficial type on endoscopy showed a significantly higher CR rate than cases with other type (P = .016).
As t(11;18)(q21;q21)/API2-MALT1 translocation was detected in only 1 case, no significant difference was identifiable, probably due to patient enrollment bias.
| Relapse and duration of complete remission
During follow-up, relapse of MALT lymphoma was observed in 4 of 81 patients (4.9%). In the remaining 77 patients (95.1%) achieved CR by H. pylori eradication therapy, CR was maintained until the end of the observation period without any additional treatment. 
| Secondary treatment for non-responders and relapsed cases
Among the 97 patients in the efficacy analysis set, 10 (10.3%) were transferred to secondary treatments. These 10 patients included 3 of the 4 relapsed patients who had initially achieved CR, and 7 of the 13 patients who did not achieve CR after successful H. pylori eradication.
Secondary treatments included radiotherapy in 7 patients, rituximab monotherapy in 1 patient, radiotherapy combined with rituximab in 1 patient, and surgical resection in 1 patient with concomitant gastrointestinal stromal tumor of the stomach. Six of the 13 patients who did not achieve CR after successful H. pylori eradication therapy were followed up under a watch-and-wait strategy. (4 patients relapsed after CR, 13 patients were non-CR) (Figure 1 ). 
| Overall survival
| Other cancers
Other cancers detected after the start of eradication therapy were 
| Safety
Adverse reactions for H. pylori eradication were recorded in 3 of 107 patients (2.8%), comprising rash in 1 case, drug eruption in 1 case, and diarrhea and dysgeusia in 1 case. Apart from drug eruption, these reactions resolved spontaneously after the completion of eradication therapy. Only 1 patient developed a serious adverse reaction, the drug eruption, who was needed intravenous administration of prednisolone, and the reaction was attributed to penicillin allergy. [17] [18] [19] [30] [31] [32] [33] including the present investigation, of 47-120 patients. The present study (n = 97) represents the third largest among these prospective studies. Overall CR rates were 85.4% (579/678) in all treated patients. Rates of relapse and treatment failure were 4.3% (25/579) and 14.5% (98/678), respectively. The combined CR rate in the 8 prospective studies (85.4%) was significantly higher than in above 9 retrospective studies (80.8%, Table 2 ) (P = .014, Fisher's exact probability test). Although the influence of other factors affecting CR rate besides clinical stage cannot be excluded in each study, this statistical difference might be meaning in the evaluation of H. pylori eradication treatment to gastric MALT lymphoma. As the influence of follow-up bias is likely to observe in retrospective studies (dropout in regression cases during follow-up), the exact CR rate of gastric MALT lymphoma by H. pylori eradication treatment should be evaluated by the accumulation of prospective studies.
| D ISCUSS I ON
Because gastric MALT lymphoma shows a slow progression and an excellent prognosis generally, one option is to adopt a watch-andwait approach using endoscopy and suitable histopathology, as long as no deterioration of any remaining lymphoma is recognized. 34 The National Comprehensive Cancer Network guideline recommends adopting a watch-and-wait strategy for 6 months after successful eradication in symptom-free cases, even if lymphoma remains. 6 In the present study, 1 of the 4 patients relapsed after achieving CR TA B L E 2 Review of the literature on efficacy of Helicobacter pylori eradication for H. pylori-positive gastric MALT lymphoma: Retrospective studies 
CR cases (%)
No.
Pinotti ( 16 (24) 23 (27) Andriani ( 13 (31) 16 (27) Ono ( 144 (14) CR, complete remission.
a Relapse, progressive disease, and/or non-CR at 6 months after eradication.
and followed using a watch-and-wait strategy obtained a second CR during the follow-up period, while 6 of 13 non-CR patients were followed up using a watch-and-wait strategy, but did not achieved PD without secondary therapy. The duration of watch-and-wait before transfer to secondary treatment was >6 months in 80% (8/10) and ≥1 year in 50% (5/10) in this study.
Several limitations must be considered in the present study. CR rate, 95% CR maintenance rate, a secondary treatment transfer rate of only 10%, and a 97% survival rate, and was associated with excellent prognosis in clinical practice. RPZ-based triple therapy
showed an H. pylori eradication rate of about 90% and was associated with only a small number of well-known adverse reactions. We therefore concluded that RPZ-based H. pylori eradication therapy is clinically useful and can be recommended as first-line treatment for H. pylori-positive localized gastric MALT lymphoma in Japan.
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